OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research report report published on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock.

OKYO Pharma Stock Performance

OKYO stock opened at $1.09 on Tuesday. OKYO Pharma has a 52-week low of $0.81 and a 52-week high of $1.90. The stock’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.07.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.